Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Schmidt, Marcus; Kuemmel, Sherko; Ruf-Doerdelmann, Antonia et al.
Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin (R)) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)ANTICANCER RESEARCH. Bd. 41. H. 1. 2021 S. 485-496
Lueftner, Diana; Tesch, Hans; Schmidt, Marcus et al.
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET studyEUROPEAN JOURNAL OF CANCER. Bd. 150. 2021 S. 268-277
Luftner, Diana; Tesch, Hans; Schmidt, Marcus et al.
Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: HTA-driven analyses from the ExteNET studyCANCER RESEARCH. Bd. 81. H. 4. 2021
Droste, A; Hönig, A; Hasenburg, A et al.
Neue Erkenntnisse vom San Antonio Breast Cancer Symposium 2020.Frauenarzt. Bd. 62. H. 3. 2021 S. 172-176
Pons, Miriam; Zeyn, Yanira; Zahn, Stella et al.
Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis InhibitionCANCERS. Bd. 13. H. 14. 2021
Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar et al.
Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Schwab, Roxana; Anic, Katharina; Stewen, Kathrin et al.
Pain experience and social support of endometriosis patients during the COVID-19 pandemic in Germany - results of a web-based cross-sectional surveyPLOS ONE. Bd. 16. H. 8. 2021
Schmidt, M
Pathologie, Prognose und PrädiktionUntch / Harbeck / Thomssen (Hrsg). Colloquium Senologie 2021 / 2022. München: Agileum 2021
Krajnak, Slavomir; Decker, Thomas; Schollenberger, Lukas et al.
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 147. H. 11. 2021 S. 3391-3400
Marme, Frederik; Stickeler, Elmar; Furlanetto, Jenny et al.
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021